CompanyGraph
HUTCHMED
0013 · HKEX · Hong Kong
Price data from its HCM listing on LSE, quoted in GBp
hutch-med.comFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.46B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.76: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
19.32BHKD2.46B · vs all stocks (USD)
Trailing P/E
125.50xRevenue (TTM)
4.31BHKD549.32M · vs all stocks (USD)
Profit Margin
3.26%Beta
0.4380xvs all stocks
52-Week Change
-19.18%vs all stocks
Market Capitalization
19.32BHKD2.46B · vs all stocks (USD)
Enterprise Value
126.98BHKD16.19B · vs all stocks (USD)
Trailing P/E
125.50xForward P/E
34.75xPrice to Sales (TTM)
31.78xPrice to Book (MRQ)
1.76xEnterprise to Revenue
29.47xGross Margin
23.08%Profit Margin
3.26%Operating Margin
0.31%Return on Assets (TTM)
-1.24%Return on Equity (TTM)
1.46%Revenue (TTM)
4.31BHKD549.32M · vs all stocks (USD)
Revenue per Share (TTM)
0.6370HKDUpdated Aug 18, 2026Quarterly Revenue Growth
0.20%Gross Profit (TTM)
573.62MHKD73.13M · vs all stocks (USD)
Net Income (TTM)
140.32MHKD17.89M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-96.50%Operating Cash Flow (TTM)
160.54MHKD20.47M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-148.15MHKD-18.89M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00HKDUpdated Aug 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
13.34MUSDFY2025 · Dec 31, 2025Revenue
548.51MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
336.35MUSDFY2025 · Dec 31, 2025Gross Profit
212.16MUSDFY2025 · Dec 31, 2025Operating Income
-35.70MUSDvs all stocks (USD)
Pre-tax Income
498.69MUSDFY2025 · Dec 31, 2025Income Tax Expense
63.61MUSDFY2025 · Dec 31, 2025Net Income
457.73MUSDFY2025 · Dec 31, 2025EBIT
501.56MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
36.02MUSDFY2025 · Dec 31, 2025Research & Development
148.29MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
103.03MUSDFY2025 · Dec 31, 2025Other Operating Expenses
5.51MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
49.88MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.87MUSDFY2025 · Dec 31, 2025EPS (Basic)
0.5300USDFY2025 · Dec 31, 2025EPS (Diluted)
0.5300USDFY2025 · Dec 31, 2025Basic Shares Outstanding
858.28MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
858.28MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
457.73MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-823.00KUSDFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00USDFY2025 · Dec 31, 2025Operating Cash Flow
459.56MUSDFY2025 · Dec 31, 2025Free Cash Flow
445.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
71.33MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
457.73MUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.29MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.57MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
24.22MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-39.26MUSDFY2025 · Dec 31, 2025Capital Expenditures
-14.12MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-10.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
608.50MUSDFY2025 · Dec 31, 2025Purchase of Investments
-2.74BUSDFY2025 · Dec 31, 2025Sale of Investments
2.13BUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-19.41MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
30.90MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-24.64MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
7.84MUSDFY2025 · Dec 31, 2025Shares Outstanding
859.74MSharesUpdated Aug 18, 2026Float Shares
522.94MSharesUpdated Aug 18, 2026% Held by Insiders
38.80%vs all stocks
% Held by Institutions
19.42%vs all stocks
Total Cash (MRQ)
10.80BHKD1.38B · vs all stocks (USD)
Total Cash per Share (MRQ)
1.58HKDUpdated Aug 18, 2026Total Debt (MRQ)
741.56MHKD94.54M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0741xCurrent Ratio (MRQ)
5.64xBook Value per Share (MRQ)
11.39HKDUpdated Aug 18, 2026Total Assets
1.75BUSDvs all stocks (USD)
Total Current Assets
1.57BUSDFY2025 · Dec 31, 2025Total Liabilities
501.83MUSDFY2025 · Dec 31, 2025Total Non-current Assets
185.75MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
186.06MUSDFY2025 · Dec 31, 2025Total Current Liabilities
315.77MUSDFY2025 · Dec 31, 2025Cash
57.32MUSDFY2025 · Dec 31, 2025Cash Equivalents
14.01MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
71.33MUSDFY2025 · Dec 31, 2025Other Short-term Investments
1.30BUSDFY2025 · Dec 31, 2025Accounts Receivable
126.75MUSDFY2025 · Dec 31, 2025Inventory
41.13MUSDFY2025 · Dec 31, 2025Accounts Payable
45.53MUSDFY2025 · Dec 31, 2025Short-term Debt
27.85MUSDFY2025 · Dec 31, 2025Other Current Liabilities
250.00KUSDFY2025 · Dec 31, 2025Long-term Debt
70.04MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
9.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
87.23MUSDFY2025 · Dec 31, 2025Retained Earnings
-378.64MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
1.25BUSDvs all stocks (USD)
52-Week Low
15.57HKDUpdated Aug 18, 202652-Week High
28.80HKDUpdated Aug 18, 202652-Week Change
-19.18%vs all stocks
Beta
0.4380xvs all stocks
50-Day MA
17.68HKDUpdated Aug 18, 2026200-Day MA
21.10HKDUpdated Aug 18, 2026Avg 10-Day Volume
4.94MSharesUpdated Aug 18, 2026Avg 30-Day Volume
3.67MSharesUpdated Aug 18, 2026Diluted EPS (TTM)
0.1600HKDUpdated Aug 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 31.78Revenue Growth YoY: 0.00
Financial Health
Altman Z-Score 4.76: safe zoneNotable
Altman Z-Score: 4.76
High structural barrier to entryNotable
Barrier to Entry: 1.04
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.46B, above the global median of $1.15BNotable
Market cap (USD): 2,462,843,451.301Global Median: 1,146,734,693.424
Revenue is $549.32M, above the global median of $520.53MNotable
Revenue (USD): 549,319,233.597Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Curaleaf Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nurix Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Mineralys Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk